Please login to the form below

Not currently logged in
Email:
Password:

BMS melanoma drug meets goal

Bristol-Myers Squibb has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study

Bristol-Myers Squibb (BMS) has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study.

The trial, known as study 024, showed that ipilimumab improved overall survival in previously untreated patients with unresectable stage III or stage IV melanoma. The trial compared the BMS drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

BMS said it plans to submit an abstract of the data to the American Society of Clinical Oncology for presentation at the society's Annual Meeting this summer.

BMS has already filed the drug with the US Food and Drug Administration (FDA), as well as regulatory authorities in a number of other countries, as a therapy for previously treated unresectable stage III or stage IV melanoma patients. In the US, a decision regarding the drug for that indication is due within days.

22nd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics